NCT01828008Unknown不适用
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Han weidong0 个研究点目标入组 20 人开始时间: 2013年4月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 主要终点
- disease free survival
研究概览
简要总结
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
详细描述
Autologous CIK transfusion within 3 days post CD20 antibody treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy
排除标准
- •to refuse the therapy and need not tolerate the therapy
结局指标
主要结局
disease free survival
时间窗: 5 years
次要结局
未报告次要终点
研究者
Han weidong
combination of anti-CD20 with CIK for refractory lymphomas
Chinese PLA General Hospital
相似试验
Unknown
早期 1 期
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological MalignanciesCARNCT04700319PersonGen BioTherapeutics (Suzhou) Co., Ltd.30
进行中（未招募）
1 期
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT06464185Institute of Hematology & Blood Diseases Hospital, China53
Unknown
1 期
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell LymphomaB-Cell Lymphoma Stage IRefractoryRelapsedNCT03881761Henan Cancer Hospital50
已完成
不适用
Anti-CD20 treatment of relapsed or refractory immune thrombocytopaenic purpura (ITP) after first line corticosteroid treatmentImmune thrombocytopaenic purpura (ITP)Haematological DisordersPurpura and other haemorrhagic conditionsISRCTN16619820Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands) - Data Centre150
已完成
不适用
Anti-CD20 treatment of relapsed or refractory Immune Thrombocytopenic Purpura (ITP) after first line corticosteroid treatment.NL-OMON23430150